Sign in

CIK 0001815442

  • Large accelerated filer

Kymera Therapeutics, Inc.

Sign in to watch
Ticker
KYMR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
812992166
Phone
+1 857-285-5314
Business address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
Former names
Kymera Therapeutics, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Planned sale Director sold 4,500 shares at $50.00 ($225,000)
  3. 4 Planned sale Director sold 5,000 shares at $49.04 ($245,186)
  4. 4 Planned sale Director sold 12,000 shares at an average $46.10 ($553,200)
  5. 4 Planned sale Chief Executive Officer sold 30,000 shares at $49.00 ($1,470,000)
  6. 4 Planned sale Director sold 6,349 shares at $49.00 ($311,101)
  7. 4 Open-market sale Chief Operating Officer sold 2,575 shares at $29.30 ($75,436)
  8. 4 Grant or award Chief Business Officer acquired 50,000 shares (grant or award)
  9. 3 Insider Initial Statement of Ownership
  10. 4 Exercise or conversion Chief Financial Officer acquired 25,000 shares (option exercise)
  11. 4 Open-market sale Chief Legal Officer sold 2,241 shares at an average $30.45 ($68,239)
  12. 4 Open-market sale Chief Operating Officer sold 1,383 shares at an average $30.45 ($42,113)
  13. 4 Open-market sale Chief Financial Officer sold 7,035 shares at an average $30.45 ($214,219)
  14. 4 Derivatives Options or other derivatives
  15. 4 Open-market sale Chief Medical Officer sold 5,740 shares at an average $30.45 ($174,786)
  16. 4 Exercise or conversion Chief Executive Officer acquired 10,000 shares (option exercise)
  17. 4 Exercise or conversion Chief Financial Officer acquired 10,000 shares (option exercise)
  18. 4 Open-market sale Chief Legal Officer sold 3,129 shares at $41.75 ($130,645)
  19. 4 Planned sale Director sold 2,500 shares at $49.00 ($122,500)
  20. 4 Planned sale Director sold 13,500 shares at an average $48.28 ($651,766)

Page 5 of 15 · 296 filings